Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Other Non-Current Liabilities (2018 - 2023)

China Pharma Holdings filings provide 10 years of Other Non-Current Liabilities readings, the most recent being $2.2 million for Q1 2023.

  • On a quarterly basis, Other Non-Current Liabilities changed N/A to $2.2 million in Q1 2023 year-over-year; TTM through Mar 2023 was $2.2 million, a N/A change, with the full-year FY2022 number at $2.4 million, up 26.85% from a year prior.
  • Other Non-Current Liabilities hit $2.2 million in Q1 2023 for China Pharma Holdings, down from $2.4 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $3.1 million in Q2 2021 to a low of $1.7 million in Q3 2021.
  • Median Other Non-Current Liabilities over the past 5 years was $2.4 million (2022), compared with a mean of $2.3 million.
  • Biggest five-year swings in Other Non-Current Liabilities: plummeted 31.44% in 2021 and later rose 26.85% in 2022.
  • China Pharma Holdings' Other Non-Current Liabilities stood at $2.4 million in 2019, then grew by 14.44% to $2.7 million in 2020, then plummeted by 31.44% to $1.9 million in 2021, then grew by 26.85% to $2.4 million in 2022, then dropped by 9.15% to $2.2 million in 2023.
  • The last three reported values for Other Non-Current Liabilities were $2.2 million (Q1 2023), $2.4 million (Q4 2022), and $1.9 million (Q4 2021) per Business Quant data.